- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07605832
Children With Surgically Corrected Acyanotic Congenital Heart Disease (Pediatrics)
The goal of this quasi-experimental pretest-posttest controlled study is to learn whether moderate-intensity treadmill exercise can improve gait kinematics, walking capacity, and motor performance in preschool children aged 48-72 months with surgically corrected acyanotic congenital heart disease.
The main questions it aims to answer are:
Does moderate-intensity treadmill training improve gait kinematics, including stride length, walking speed, and double-stance percentage? Does moderate-intensity treadmill training improve walking capacity and balance in children with surgically corrected acyanotic congenital heart disease?
Researchers compared children with surgically corrected acyanotic congenital heart disease who received treadmill training with age-matched healthy children to see whether the exercise program could reduce gait, balance, and walking-capacity differences between the groups.
Participants with congenital heart disease completed:
Four treadmill walking sessions per week for 10 weeks. Moderate-intensity walking at approximately 70% of maximal heart rate. Pre- and post-intervention assessments of gait kinematics using three-dimensional motion analysis.
Balance assessment using the Pediatric Balance Scale. Walking capacity assessment using the six-minute walk test.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Gamasa, Egypt, 35712
- Amira Hussin Mohammed
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
For cyanotic postoperative congenital heart disease group:
- Children diagnosed with acyanotic postoperative congenital heart disease.
- Underwent surgical repair for CHD.
- Has a history of only one surgical intervention.
- Age between 48 and 72 months.
Mentally normal, with an IQ between 85 and 115.
For the healthy control group (HCG):
- For healthy children aged 48 to 72 months. Full school attendance. Full participation in social and recreational activities. Parents/guardians provided written informed consent.
Exclusion Criteria:
Children were excluded if they had:
- Genetic disorders.
- Severe neurological disorders.
- Cyanotic congenital heart disease.
- Perinatal complications.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: congenital heart disease
The children in this group received walking sessions weekly for 10 weeks.
|
4 sessions of walking on treadmill for 2.5 months
|
|
Ingen inngripen: healthy group
health control group
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
gait parameters
Tidsramme: basiline pre-test assessment and after 10 weeks of interventions (post-intervention assessment)
|
Gait parameters, including stride length (cm), speed (meters/minute), and double stance percentage (%) of the dominant leg, were assessed using a 3D motion analysis system.
|
basiline pre-test assessment and after 10 weeks of interventions (post-intervention assessment)
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- Acyanotic Heart Disease
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .